# A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

Source: https://onco.cc/trials/nct06885385/  
OnCo record `nct06885385` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Shanghai Junshi Bioscience Co., Ltd., now recruiting.

## Summary

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer is a phase 2, interventional study registered as NCT06885385 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 60 participants, started 2025-04-23 and due to reach its primary completion in 2026-11-27. Interventions recorded: JS207; JS015; Capecitabine; Oxaliplatin. Conditions listed: Advanced Colorectal Cancer. Primary outcome: Dose-limiting toxicity （DLT); Adverse event（AE）; RP3D. Colorectal eligibility wording from the registry: "Colorectal adenocarcinoma or rectal adenocarcinoma with histological or cytological Qualification, according to the 8th edition of the AJCC colorectal cancer TNM staging stage IV, MSS/pMMR (a qualified report of MSS or pMMR detected by a local laboratory must be provided), and no previous systemic a". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06885385
- Phase: 2
- Setting: An Open-label, Multicenter, Phase 2 Clinical Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy (XELOX) as First-line (1L) Treatment in Patients With MSS/pMMR Advanced Colorectal Cance
- Sponsor: Shanghai Junshi Bioscience Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06885385: https://clinicaltrials.gov/study/NCT06885385

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- companies: [Shanghai Junshi Biosciences](https://onco.cc/companies/junshi/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06885385.json